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Abstract
Neurodegenerative disorders are associated with impaired cognitive function and worse
physical health outcomes. This study aims to test whether polygenic risk for Alzheimer’s dis-
ease, Amyotrophic Lateral Sclerosis (ALS), or frontotemporal dementia (FTD) is associated
with cognitive function and physical health in the UK Biobank, a cohort of healthy individuals.
Group-based analyses were then performed to compare the top and bottom 10% for the
three neurodegenerative polygenic risk scores; these groups were compared on the cogni-
tive and physical health variables. Higher polygenic risk for AD, ALS, and FTD was associ-
ated with lower cognitive performance. Higher polygenic risk for FTD was also associated
with increased forced expiratory volume in 1s and peak expiratory flow. A significant group
difference was observed on the symbol digit substitution task between individuals with high
polygenic risk for FTD and high polygenic risk for ALS. The results suggest some overlap
between polygenic risk for neurodegenerative disorders, cognitive function and physical
health.
Introduction
Alzheimer’s disease (AD) is the most common form of dementia and it is expected that over
one million people in the UK will be diagnosed with this disease by 2025 [1]. Approximately
10% of individuals over the age of 65 have AD, increasing in prevalence with age [2].
PLOS ONE | https://doi.org/10.1371/journal.pone.0198187 June 1, 2018 1 / 13
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Hagenaars SP, Radaković R, Crockford C,
Fawns-Ritchie C, International FTD-Genomics
Consortium (IFGC), Harris SE, et al. (2018) Genetic
risk for neurodegenerative disorders, and its
overlap with cognitive ability and physical function.
PLoS ONE 13(6): e0198187. https://doi.org/
10.1371/journal.pone.0198187
Editor: Lisa Chakrabarti, University of Nottingham,
UNITED KINGDOM
Received: December 20, 2017
Accepted: May 14, 2018
Published: June 1, 2018
Copyright: © 2018 Hagenaars et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data from the UK
Biobank (www.ukbiobank.ac.uk) are third party and
legal constraints do not permit public sharing of
the data. The UK Biobank data used in this study
can be accessed by applying through the UK
Biobank Access Management System (www.
ukbiobank.ac.uk/register-apply). The data
generated by the International FTD-Genomics
Consortium (IFGC) are available upon request to
protect patient information; the IFGC can be
Pathological features of AD include amyloid B-plaques and neurofibrillary tangles [3], while
degeneration of subcortical hippocampal regions and the medial temporal lobes is associated
with the salient presenting memory impairment [4, 5].
Frontotemporal dementia (FTD), distinct from AD, is marked by degeneration of the fron-
tal and anterior temporal lobes. FTD is the second most prevalent presentation of early onset
dementia, accounting for approximately 3–26% of cases [6]. Behavioural variant FTD is the
most common phenotype, and is defined by behaviour change and executive dysfunction (e.g.,
impairments in working memory, cognitive flexibility, response generation, and social cogni-
tion), with relative sparing of episodic memory and visuospatial skills [7]. FTD shares genetic,
pathological, and neuropsychological overlap with Amyotrophic Lateral Sclerosis (ALS). ALS
is a neurodegenerative disease marked by progressive loss of motor neurons in the brain and
spinal cord, resulting in muscle wasting, spasticity, and death usually due to respiratory failure
within three years [8]. Approximately 35% of ALS patients will present with mild cognitive
and/or behavioural changes, of a similar nature to those seen in FTD, with an additional 15%
meeting diagnostic criteria for both ALS and FTD [9]. Similarly, approximately 40% of FTD
patients present with motor symptoms, and 15% meet ALS classification criteria [10].
The genetic aetiology of AD and FTD/ALS is heterogeneous. The APOE e4 allele is the
strongest risk factor for late onset AD; however, numerous additional candidate and suscepti-
bility loci have been established in recent years [11]. It has been suggested that late onset AD is
due to susceptibility at multiple loci, and due to genetic and environmental interactions [12].
Conversely, early onset AD is autosomal dominant, accounting for approximately 1–5% of all
cases, has been linked to variants in the APP, PSEN1, and PSEN2 genes [13]. Autosomal domi-
nant ALS accounts for approximately 5–10% of cases, with 85–90% of cases having no strong
genetic linkage [14]. Familial ALS has been linked to the SOD1, TARDBP, FUS, and more
recently NEK1 genes [15, 16]. FTD shows a positive family history in up to 40% of cases, with
mutations in the MAPT and GRN genes being amongst the most common [17]. The C9ORF72
mutation has been most frequently associated with familial ALS and FTD [18, 19] but can also
be found in sporadic forms of both diseases [20, 21], however the cause here is often unknown,
and possibly due to environmental-genetic linkages [15]. A genome-wide association study
(GWAS) of FTD [22] demonstrated that the C9ORF72 mutation mainly associates with the
ALS-FTD variant indicating a strong genetic overlap.
In addition to the genetic complexity, the cognitive profiles of AD and FTD/ALS are het-
erogeneous, in that impairments in executive functions, language, visuospatial skills, and
memory have been recorded in all three diseases [23]. Whereas evidence does exist that mem-
ory, visuospatial, and particularly language functions may be affected in FTD, the extent to
which executive dysfunction explains these observations remains unclear [24, 25]. Previous
research has suggested a preclinical phase of reduced cognitive functioning for older adults
who subsequently develop AD [26] and for those at genetic risk of developing AD [27–31],
with similar findings reported for FTD [32, 33]. Yet, not all those at genetic risk of developing
AD or FTD/ALS go on to develop the disease, and these findings may suggest that genetic car-
riers may be at risk of developing preclinical symptoms without necessarily developing the dis-
ease itself. Furthermore, the genetic aetiology of AD, ALS, and FTD is multifactorial, and a
significant proportion of genetic variance remains unexplained (that is, there is missing herita-
bility [34]).
As such, polygenic risk scores are becoming increasingly useful in the study of genetically
complex diseases. Polygenic risk scores are valuable in aggregating genetic markers that on
their own do not reach significance [35]. Higher polygenic risk for AD, based on genome-wide
significant single nucleotide polymorphisms (SNPs) [36] and all common SNPs [37], has been
associated with lower general cognitive ability and memory. Some research has suggested that
Genetic overlap between neurodegenerative disease, cognitive ability and physical function
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healthy adults with a high polygenic risk for AD possess reduced brain cortical thickness [38].
Polygenic risk has been associated with cognitive performance in other diseases; for instance, a
high polygenic risk of schizophrenia has been associated with a greater decline in cognitive
functioning between childhood and older age [39], and reduced neural efficiency [40]. Simi-
larly, high polygenic risk for autism has been associated with better cognitive ability in the gen-
eral population [37, 41]. To date however, no identifiable research has explored whether
polygenic risk for FTD or ALS is associated with cognitive, muscle, or respiratory function.
As such, the aim of this study is to extend the work accomplished in AD to FTD/ALS, and
to further explore whether polygenic risk for AD, FTD, or ALS is associated with cognitive per-
formance, or with physical function measures known to be affected by motor neuron
degeneration.
Materials and methods
Sample
This study includes baseline data and data from a web-based cognitive follow-up from the UK
Biobank study, a large resource for identifying determinants of human diseases in middle aged
and older healthy individuals (http://www.ukbiobank.ac.uk) [42]. A total 502,655 community-
dwelling participants aged between 37 and 73 years were recruited between 2006 and 2010 in
the United Kingdom, and underwent extensive baseline testing including cognitive and physi-
cal assessments. All participants provided blood, urine and saliva samples for future analysis.
For the follow up testing, participants completed cognitive tests remotely via a web-based
assessment.
Measures
Cognitive measures. Cognitive ability was measured using five different cognitive tests.
These included tests of verbal-numerical reasoning (n = 36,035), reaction time (n = 111,484),
memory (n = 112,067), trail making (part A: n = 23,822, part B: n = 23,812), and symbol digit
substitution (n = 26,913). The verbal-numerical reasoning test consisted of a 13-item question-
naire assessing verbal and arithmetical deduction (Cronbach α reliability of 0.62). Reaction
time was measured using a computerized ‘Snap game’, during which participants were asked
to press a button as quickly as possible when two cards on the screen were matching. There
were eight trials, four had matching cards and required the button to be pressed (Cronbach α
reliability of 0.85). Memory was measured using a pairs matching test, where participants were
asked to memorize positions of matching pairs of cards, shown for 5s on a 3 by 4 grid. All
cards were then placed face down and the participant had to identify the positions of the
matching pairs as quickly as possible. The number of errors in this task was used as the
(inverse) measure of memory ability. These tests have been previously described in more detail
by Hagenaars et al. (2016)[37]. Executive functioning was measured using the trail making test
parts A (TMT A) and B (TMT B), which were part of the follow up testing wave in UK Bio-
bank, between 2014 and 2015. For TMT A, participants were instructed to connect numbers
consecutively (which were quasi-randomly distributed on the touchscreen) as quickly as possi-
ble in ascending order by selecting the next number. TMT B is similar, but in this case letters
and numbers had to be selected in alternating ascending order, e.g. 1 A 2 B 3 C etc. The differ-
ence between the raw scores for TMT A and TMT B was computed as TMT B minus TMT A
(TMT B-A). Owing to positively skewed distributions, both TMT A and TMT B scores were
log-transformed prior to further analyses. Further detail on these tests in UK Biobank has
been published previously [43]. Processing speed was measured using the symbol digit substi-
tution test, similar to the well-validated Symbol Digits Modalities Test [44], which was also
Genetic overlap between neurodegenerative disease, cognitive ability and physical function
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part of the follow up testing wave. In the UK Biobank symbol digit substitution test, partici-
pants are presented with symbols paired with digits and are asked to enter the digits that are
paired with the symbols in the empty spaces. The score for processing speed was based on the
number of correctly matched symbols. Participants who scored 0 (n = 61) or above 40 (n = 3)
were removed from further analyses, as they scored more than 4 SD away from the mean.
Physical measures. Muscle weakening and respiratory dysfunction are physical symp-
toms characteristic of ALS and in a proportion of FTD patients. Muscle strength was measured
via hand grip strength for both the right and left hand, using a Jamar J00105 hydraulic hand
dynamometer. Participants were seated upright in a chair with their forearms on the armrests,
and were asked to squeeze the handle of the dynamometer as strongly as possible for three sec-
onds. The maximum grip strength for each hand was measured in whole kilogram force units.
This study used maximum grip strength based on the dominant hand, as indicated by the
participant.
Lung (respiratory) function was assessed using a Vitalograph Pneumotract 6800 spirome-
ter. Participants were asked to record two to three blows, lasting for at least 6 seconds, within a
period of 6 minutes. The following outcomes measures were calculated by the computer:
forced expiratory volume in 1s (FEV1), forced vital capacity (FVC), and peak expiratory flow
(PEF). FEV1 is the amount of air, in litres, that is forcibly exhaled in 1 second following full
inspiration. FVC is the amount of air, in litres, that is exhaled followed full inspiration. PEF is
the maximum speed of exhalation following full inspiration. All three measures were standard-
ized and individuals with a Z-score > 4 were excluded from FEV1 (n = 47), FVC (n = 73), and
PEF (n = 28).
Genotyping and quality control
The interim release of UK Biobank included genotype data for 152,729 individuals, of whom
49,979 were genotyped using the UK BiLEVE array and 102,750 using the UK Biobank axiom
array. These arrays have over 95% content in common. Quality control was performed by
Affymetrix, the Wellcome Trust Centre for Human Genetics, and by the present authors; this
included removal of participants based on missingness, relatedness, gender mismatch, and
non-British ancestry. We only included individuals of White British ancestry to reduce popu-
lation stratification and the other ethnic groups were underpowered on their own to detect
effects. British ancestry was defined as individuals who both self-identified as White British
and were confirmed as ancestrally White British using principal components analyses (PCA)
of genome-wide genetic information, this information was provided by UK Biobank. Further
details have been published elsewhere [37, 45]. Variants with a minor allele frequency of less
than 0.01 and non-autosomal variants were excluded from further analysis. A sample of
112,151 individuals available for further analysis remained after quality control.
Polygenic risk scores
The UK Biobank genotyping data required recoding from numeric (1, 2) allele coding to stan-
dard ACGT format before being used in polygenic profile scoring analyses, this was done
using a bespoke program [37]. Polygenic risk scores were created for AD [11], ALS [21], FTD,
[22] in all genotyped participants using PRSice software [46]. PRSice calculates the sum of
alleles associated with the phenotype of interest across many genetic loci, weighted by their
effect sizes estimated from a GWAS of the corresponding phenotype in an independent sam-
ple. The GWAS summary statistics for AD, ALS, and FTD were used as the training (base)
dataset, while UK Biobank was used as the prediction (target) dataset. Clumping was used to
obtain SNPs in linkage disequilibrium with an r2< 0.25 within a 250kb window. Five
Genetic overlap between neurodegenerative disease, cognitive ability and physical function
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polygenic risk scores were then created for the three phenotypes (AD, ALS, FTD) containing
SNPs selected according to the significance of their association with the phenotype, at thresh-
olds of p< 0.01, p< 0.05, p< 0.1, p< 0.5, and all SNPs. Polygenic risk scores were also cre-
ated for AD excluding SNPs within a 500 kb window of apolipoprotein E (APOE) gene.
Statistical analysis
All statistical analyses were performed in R version 3.4.0 [47]. The associations between the
polygenic profiles and the target phenotype were examined in regression models, adjusting for
age at measurement, sex, genotyping batch and array, assessment centre, and the first 10
genetic principal components to adjust for population stratification. The models including
measures of lung function (FEV1, FVC, PEF) were also adjusted for smoking status and height,
whereas the models for grip strength were additionally adjusted for height and weight. All
models were corrected for multiple testing using the false discovery rate method [48].
Following calculation of each participant’s polygenic risk score at each of the above-men-
tioned thresholds, participants were classified in terms of their high or low polygenic risk for
each neurodegenerative disease (AD, ALS and FTD). High risk was defined by the participant’s
polygenic risk score falling within the top 10th percentile and low risk was defined by the par-
ticipant’s polygenic risk score falling within the bottom 10th percentile for any of the neurode-
generative diseases. These participants were then grouped based on High Risk for AD (top
10th percentile for AD and bottom 10th percentiles for ALS and FTD), High Risk for ALS (top
10th percentile for ALS and bottom 10th percentiles for AD and FTD) and High Risk for FTD
(top 10th percentile for FTD and bottom 10th percentiles for ALS and AD) to homogenise
pure polygenic risk for each neurodegenerative disease in these groups. There were no overlap-
ping participants in each of these groups. These High Risk for AD, High Risk for ALS and
High Risk for FTD groups were compared on cognitive and physical variables (chosen based
on significant polygenic profile-target phenotype regression models from the previous analy-
sis). Shapiro-Wilk tests were used to assess normality of the data, following which group com-
parisons were performed either using Kruskal-Wallis H or ANOVA tests on cognitive and
physical variables, applying a Holm-Bonferroni correction. Significant Kruskal-Wallis H or
ANOVA results were followed up with post hoc tests (Mann Whitney U tests, or Tukey’s Hon-
est Significant Differences, respectively), where effect size was estimated using Cohen’s d.
Results
For the present study, genome-wide genotyping data was available for 112,151 individuals
(58,914 females), aged between 40 and 70 years (mean age = 56.9 years, SD = 7.93) after the
quality control process. Table 1 shows descriptive statistics for each of the measures used in
this study.
Polygenic risk analysis
The results for the polygenic risk analyses examining if polygenic risk for neurodegenerative
diseases is associated with cognitive ability and physical health, using the best threshold (larg-
est β), are shown in Table 2 and Fig 1. Full results including all five thresholds can be found in
S1 Table. Polygenic risk scores for AD significantly predicted verbal-numerical reasoning (β =
-0.023, p = 1.27 × 10−5) [37], memory (β = 0.011, p = 0.0001) [37], symbol digit substitution
(β = -0.015, p = 0.0065), and TMT B (β = 0.017, p = 0.0047). Thus, individuals with higher
polygenic risk for AD answered fewer verbal-numerical reasoning questions correctly, made
more errors on the memory task, completed fewer items on the symbol digit substitution test,
and took longer to complete TMT B. When excluding APOE from the AD polygenic risk
Genetic overlap between neurodegenerative disease, cognitive ability and physical function
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score, the associations with symbol digit substitution attenuated to non-significance (S1
Table). Polygenic risk scores for ALS significantly predicted verbal-numerical reasoning (β =
-0.019, p = 0.0004). Individuals with higher polygenic risk for ALS had lower scores on verbal-
numerical reasoning. Polygenic risk scores for FTD significantly predicted TMT B (β = 0.017,
p = 0.0041), FEV1 (β = 0.007, p = 0.0012), and PEF (β = 0.011, p = 4.77 × 10−6). Those with
higher polygenic risk for FTD took longer to complete TMT B and had higher FEV1 and PEF
scores. The associations between all scores at each threshold are shown in S2 Table.
Table 1. Descriptive statistics for cognitive and physical function measures in UK Biobank.
N mean (SD)
Baseline cognitive tests
Verbal-numerical reasoning 36,035 6.16 (2.10)
Reaction time (time in ms) 111,483 555.10 (112.62)
Memory (errors) 112,067 4.06 (3.02)
Follow-up cognitive tests
Symbol digit substitution (correct matches) 26,913 19.74 (5.13)
Trail making part A (time in s) 23,822 39.11 (14.73)
Trail making part B (time in s) 23,812 66.44 (24.89)
Trail making part B–part A (time in s) 23,769 27.22 (18.89)
Physical function
Grip strength (in kg) 111,735 32.17 (11.35)
Forced expiratory volume in 1s (in litres) 104,722 2.79 (0.81)
Peak expiratory volume (in litres/min) 104,741 389.20 (135.42)
Forced vital capacity (in litres) 104,696 3.71 (1.01)
Demographics
Age at baseline (in years) 112,151 56.91 (7.93)
Age at follow-up (in years) 27,429 63.00 (7.61)
Gender, female N (%) 112,151 58,914 (52.53)
College degree obtained, yes (%) 112,151 33,852 (30.20)
https://doi.org/10.1371/journal.pone.0198187.t001
Table 2. Associations between polygenic risk scores for Alzheimer’s disease (FDR p-value 0.018), amyotrophic lateral sclerosis (FDR p-value 0.0024), and fron-
totemporal dementia (FDR p-value 0.0041), and cognitive and physical measures controlling for age, sex, assessment centre, genotyping batch and array and 10
genetic principal components for population structure.
Alzheimer’s disease Amyotrophic lateral sclerosis Frontotemporal dementia
pT β p pT β p pT β p
Verbal-numerical reasoning 0.05 -0.0229 1.27 × 10−5

0.05 -0.0188 0.0004 1 -0.0085 0.1036
Reaction time 0.5 0.0052 0.0700 1 0.0023 0.4315 0.5 -0.0033 0.2489
Memory 0.1 0.0114 0.0001 0.1 0.0080 0.0074 0.05 0.0053 0.0737
Symbol digit substitution 0.5 -0.0150 0.0065 0.01 -0.0063 0.2613 0.01 -0.0053 0.3316
Trail making part A 0.05 0.0144 0.0195 0.01 0.0087 0.1609 0.1 0.0104 0.0900
Trail making part B 0.5 0.0168 0.0047 0.1 0.0155 0.0101 0.1 0.0171 0.0041
Trail making part B-A 1 0.0104 0.0965 0.1 0.0166 0.0091 0.1 0.0093 0.1410
Grip strength 0.1 -0.0016 0.3963 0.01 0.0032 0.0997 0.05 0.0020 0.2911
Forced expiratory volume in 1s 1 -0.0027 0.2018 0.01 0.0022 0.3066 0.05 0.0068 0.0012
Peak expiratory flow 1 -0.0039 0.1159 0.01 0.0017 0.4943 0.1 0.0113 4.77 × 10−6
Forced vital capacity 1 -0.0014 0.4817 0.01 0.0019 0.3158 0.05 0.0027 0.1628
pT, polygenic risk score threshold for best model
, previously published by Hagenaars et al., (2016) [37]
https://doi.org/10.1371/journal.pone.0198187.t002
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Polygenic inter-group comparison
Table 3 shows the comparison of polygenic risk groups on cognitive and physical variables.
There was no significant difference between those categorised as having high polygenic risk
for AD, ALS, or FTD on age or gender distribution. The only significant difference between
these groups was observed with one of the cognitive variables, specifically, symbol digit substi-
tution task. Follow up, post hoc analysis showed that participants with a high polygenic risk
for FTD performed significantly worse on the symbol digit substitution task when compared
to participants with a high polygenic risk for ALS (U = 396, p< 0.01, d = 0.85). No significant
differences were observed between other groups on cognitive and physical variables.
Discussion
The present study aimed to explore whether polygenic risk for AD, FTD, or ALS is associated
with cognitive performance, grip strength, or lung function measures. Using the large
Fig 1. Heat map of associations between the polygenic profile scores for neurodegenerative disease and cognitive ability and physical
health. Stronger associations are indicated by darker shades, red indicates a positive association, blue indicates a negative association. AD,
Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; TMT B-A, trail-making part B–part A; TMT B, trail
making part B; TMT A, trail making part A; DSS, digit symbol substitution; VNR, verbal numerical reasoning; FVC, forced vital capacity; PEF,
peak expiratory flow; FEV1, forced expiratory volume in 1s. , significant association after FDR correction (p-value 0.018 (AD), 0.024 (ALS),
or 0.0041 (FTD)). Full results can be found in S1 Table.
https://doi.org/10.1371/journal.pone.0198187.g001
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cognitive, physical and genotypic data available in the UK Biobank, in concordance with the
most up to date GWAS consortia of neurodegenerative disease (AD, ALS and FTD), our
results showed a novel relationship between cognitive and physical function variables and
polygenic risk for neurodegenerative conditions in a healthy population, particularly in the
case of AD.
The findings of this study demonstrate that higher polygenic risk of AD is associated with
numerous cognitive functions; specifically, reduced performance in verbal-numerical reason-
ing, memory, processing speed (symbol digit substitution), and executive functioning (TMT
B). Sensitivity analysis indicated that the association between AD and cognitive ability (except
symbol digit substitution) was not driven by the APOE gene. Although an association between
polygenic risk of AD and cognitive ability–that is significant associations with verbal-numeric
reasoning and memory—in UK Biobank have been reported previously [37], the present study
extends these findings to measures of executive functioning and processing speed. Unlike AD,
higher polygenic risk for ALS demonstrated only one significant relationship with cognitive
function, namely verbal-numerical reasoning. Higher polygenic risk for FTD was only associ-
ated with reduced performance on the TMT B.
Physical function measures used in this study were chosen based on their relevance in clini-
cal cases of FTD and ALS, in particular, measures of grip strength and lung function. Counter-
intuitively higher risk of FTD was related to better respiratory functioning (FEV1 and PEF).
Finally, a higher risk of ALS was not associated with grip strength or measures of lung func-
tion. It is worth noting, however, that the amount of variance explained by the polygenic risk
scores was very small (< 0.01%). As such, these finding may be spurious.
In a small subset of participants, those with a high polygenic risk for FTD performed worse
on a processing speed task (symbol digit substitution task) compared to those with high poly-
genic risk for ALS. There has been an emphasis on linkage and continuum-based relationship
Table 3. Cognitive and physical variable comparison between high Alzheimer’s disease (AD) polygenic risk, amyotrophic lateral sclerosis (ALS) polygenic risk, and
frontotemporal dementia (FTD) polygenic risk, N for each group is shown.
High Risk AD High Risk ALS High Risk FTD p-value
Age 56.93 ± 7.81
(n = 389)
57.24 ± 7.75
(n = 386)
57.07 ± 7.95
(n = 343)
0.86
Gender (M/F) 179/210 188/198 157/186 0.67
Cognitive
Trail making part B‡ 4.10 ± 0.34
(n = 27)
4.05 ± 0.40
(n = 25)
4.15 ± 0.24
(n = 17)
1.00†
Verbal-numerical reasoning 6.50 ± 2.40
(n = 28)
6.22 ± 1.91
(n = 40)
6.42 ± 2.02
(n = 24)
1.00†
Memory 4.12 ± 3.26
(n = 107)
4.09 ± 2.98
(n = 112)
3.72 ± 2.73
(n = 103)
1.00†
Symbol digit substitution 19.77 ± 5.59
(n = 30)
22.16 ± 5.47
(n = 25)
17.57 ± 5.34
(n = 21)
0.04†
Physical
FEV1 2.78 ± 0.70
(n = 112)
2.84 ± 0.84
(n = 93)
2.66 ± 0.72
(n = 84)
0.62†
PEF 383.09 ± 124.25
(n = 92)
398.06 ± 138.79
(n = 101)
394.27 ± 125.92
(n = 96)
0.62†
‡Log transformed
†Kruskal-Wallis H test; Chi Squared tests used for gender distribution comparison; Mean ± Standard Deviation shown for each high neurodegenerative disease
polygenic risk group; bold text indicate significance adjusted for multiple comparisons (Holm-Bonferroni)
https://doi.org/10.1371/journal.pone.0198187.t003
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between ALS and FTD, this finding based on pure genetic risk could provide insight towards
sub-clinical cognitive impairment. The cognitive profile of ALS largely mirrors that of FTD,
albeit in a milder form. Patients with FTD have demonstrated processing speed impairments,
both cross-sectionally and longitudinally [49, 50]. However, studies of cognition in ALS have
largely ignored tasks of processing speed due to the confounding presence of motor
impairment in this patient group. That said, current research suggests unaffected processing
speed in patients with ALS. As such, previous research combined with the findings herein may
suggest a future avenue for detecting FTD syndromes in patients with ALS. However, further
studies are needed to explore the reliability of differences between polygenic risk of FTD and
ALS, and between people diagnosed with these diseases.
There are several limitations to note regarding the present study. While the cognitive tasks
in the present study covered a number of domains, the measures are brief and non-standard-
ized. As such, the sensitivity to detect small differences in cognitive ability are limited. Addi-
tionally, due to the nature of self-administration on a computer (in case of the measures for
the symbol digit substitution test and the trail making test), the environment under which the
tasks are performed could not be fully standardised. The trail making test could be confounded
by the movement speed in older individuals, however subtracting completion time for TMT A
from TMT B completion time (TMT B-A) will partially allow the relative contributions of
movement speed to be parsed from the more complex executive functions in TMT B. Finally, a
limitation is that the polygenic inter-group comparison yielded smaller sample sizes, which
could be indicative of the rarity of ‘pure’ polygenic risk for each disease in healthy adults. The
results in this area should therefore be interpreted with caution and require larger scale repli-
cation, despite building on previous research of a smaller sample size [49, 50].
Furthermore, while it is interesting to speculate how the findings of the present study may
relate to those individuals who actually have AD, FTD, or ALS, it is important to remember
that the participants of this study were healthy individuals. Those described as high polygenic
risk for a particular disease are only at higher risk when compared to other participants of this
study. It would be incorrect to describe these individuals as being at a high risk of developing a
neurodegenerative disease more generally.
Future research may explore whether these findings replicate given more extensive and con-
trolled measures of cognitive functioning. Provided that FTD is primarily a disease marked by
changes in behaviour, the inclusion of such measures would be informative. Additionally, as pre-
vious research has suggested that reduction of cortical thickness was associated with polygenic
risk for AD in healthy adults [38], it would be informative to further explore the neural correlates
of polygenic risk for different neurodegenerative disorders (e.g. ALS and FTD) in this sample.
Conclusion
The present study confirmed and extended previous findings that polygenic risk for AD is asso-
ciated with multi-domain cognitive functioning in healthy adults. Additionally, the findings of
this study demonstrate that polygenic risk for ALS is associated with verbal-numeric reasoning,
while polygenic risk for FTD was associated with executive functioning. Physical function mea-
sures commonly affected in patients with ALS, were not associated with polygenic risk of ALS
in healthy adults. However, higher polygenic risk significantly predicted better lung function.
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